Skip to main content
. Author manuscript; available in PMC: 2015 Aug 14.
Published in final edited form as: Cell. 2014 Aug 14;158(4):764–777. doi: 10.1016/j.cell.2014.06.023

Figure 4. DDX17 controls RVFV and LACV replication in human cells.

Figure 4

A. Representative IF image of RVFV-infected U2OS cells (MOI=0.3) transfected with the indicated siRNAs 16 hpi. B. Relative percent RVFV infection as quantified by automated image analysis. Mean±SEM; *p<0.05, Student’s t-test. C. Representative RNA blot from siRNA-transfected U2OS cells infected with RVFV 16 hpi. D. Fold increase in RVFV N mRNA compared to control siRNA-treated U2OS cells as quantified by Northern. Mean±SEM; *p<0.05, Student’s t-test. E. Representative IF image of LACV-infected U2OS cells (MOI=0.3) transfected with the indicated siRNAs 16 hpi. F. Relative percent LACV infection as quantified by automated image analysis. Mean±SEM; *p<0.05, Student’s t-test. G. Representative Northern for LACV N mRNA from siRNA-transfected U2OS cells infected with LACV 16 hpi. H. U2OS cells were transfected with the indicated siRNAs and infected with RVFV for 16h. Viral protein (Gn) was monitored by immunoblot. I. Immunoblot for viral protein (GFP) from U2OS cells treated with the indicated siRNAs and infected with VSV-GFP at 16 hpi (MOI=1). J. Ifit1 mRNA expression from uninfected or VSV-infected U2OS cells treated with the indicated siRNAs at 16 hpi by qRT-PCR, normalized to uninfected siCON-treated cells. Mean±SEM. K. Ifit1 mRNA expression from uninfected or RVFV-infected U2OS cells treated with the indicated siRNAs at 16 hpi by qRT-PCR, normalized to uninfected siCON-treated cells. Mean±SEM. All data represent three independent experiments. See also Figure S4.